Candelanza, Jessa Mae G.
HRN: 21-72-69 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/16/2022
AMPICILLIN 250MG (VIAL)
08/16/2022
08/23/2022
IVT
160mg
Q12
PSNB Sec To Thickly Msaf
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes